Cited by 1,192Diabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.·2020·Diabetes Care

DOI 10.2337/dci19-0066PMC PMC6971782

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dci19-0066

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
Result
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084

Flagged first, then by citations

Show all 21 references

Sorted by citations

Items 301–400 of 1,000

Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
Ferrannini, G., Norhammar, A., Gyberg, V., Mellbin, L., & Rydén, L. (2020) · Diabetes Care · doi:10.2337/dci20-0002 · Cited by 23
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Weng, J., Zeng, L., Zhang, Y., Qu, S., Wang, X., Li, P., Fu, L., Ma, B., Ye, S., Sun, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14389 · Cited by 24
Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus
Fauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P., & Camm, A. J. (2021) · EP Europace · doi:10.1093/europace/euab184 · Cited by 22
Self-citation
Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
Qian, B.-B., Chen, Q., Li, L., & Yan, C.-F. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05590-y · Cited by 22
Urban–Rural Disparities in the Incidence of Diabetes-Related Complications in Taiwan: A Propensity Score Matching Analysis
Tai, S., He, J.-S., Kuo, C.-T., & Kawachi, I. I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9093012 · Cited by 22
Concomitant diabetes with atrial fibrillation and anticoagulation management considerations
Kreutz, R. H., Camm, A. J., & Rossing, P. R. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa182 · Cited by 22
Self-citation
Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND , LEADER and SUSTAIN ‐6 to the real‐world type 2 diabetes population in the United Kingdom
Webb, J., Mount, J., von Arx, L., Rachman, J., Spanopoulos, D., Wood, R. P., Tritton, T., Massey, O., & IDRIS, I. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14580 · Cited by 21
Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes
Nowak, M., & Grzeszczak, W. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0014 · Cited by 24
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Oiwa, A., Hiwatashi, D., Takeda, T., Miyamoto, T., Kawata, I., Koinuma, M., Yamazaki, M., & Komatsu, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad144 · Cited by 22
Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
Loreto, C. D., Minarelli, V., Nasini, G., Norgiolini, R., & Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 22
Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006–2020
Liaw, J., Harhay, M., Setoguchi, S., Gerhard, T., & Dave, C. V. (2022) · Diabetes Care · doi:10.2337/dc22-0224 · Cited by 21
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
Karimi, M. A., Chahkand, M. S. G., Dadkhah, P. A., Sheikhzadeh, F., Yaghoubi, S., Moallem, F. E., Deyhimi, M. S., Bafrani, M. A., Shahrokhi, M., & Nasrollahizadeh, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1438318 · Cited by 24
Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT)
Napoli, N., Incalzi, R. A., Gennaro, G., Marcocci, C., Marfella, R., Papalia, R., Purrello, F., Ruggiero, C., Tarantino, U., Tramontana, F., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.01.019 · Cited by 22
Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes
Qiu, M., Ding, L., & Zhou, H. (2021) · Medicine · doi:10.1097/md.0000000000025121 · Cited by 22
A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol
Sundström, J., Kristófi, R., Östlund, O., Bennet, L., Eliasson, B., Jansson, S. P. O., Leksell, J. K., Almby, K. E., Lundqvist, M., & Eriksson, J. W. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107996 · Cited by 21
Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes · doi:10.2337/db21-0777 · Cited by 20
Predictive Ability of Visit-to-Visit Variability of HbA1c Measurements for the Development of Diabetic Kidney Disease: A Retrospective Longitudinal Observational Study
Yan, Y., Kondo, N., Oniki, K., Watanabe, H., Imafuku, T., Sakamoto, Y., Shigaki, T., Maruyama, A., Nakazawa, H., Kaneko, T., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/6934188 · Cited by 23
Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
Tatsumi, T., Oshitari, T., Takatsuna, Y., Ishibashi, R., Koshizaka, M., Shiko, Y., Baba, T., Yokote, K., & Yamamoto, S. (2022) · Life · doi:10.3390/life12050692 · Cited by 21
4-OI Protects MIN6 Cells from Oxidative Stress Injury by Reducing LDHA-Mediated ROS Generation
Wu, J., Gu, X., Zhang, J., Mi, Z., He, Z., Dong, Y., Wu, G., Ghimire, K., Rong, P., Wang, W., et al. (2022) · Biomolecules · doi:10.3390/biom12091236 · Cited by 24
Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study
Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O’Neill, S., Basu, A., Silverwood, R. J., Charlton, P., Briggs, A. H., Smeeth, L. L., Adler, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14874 · Cited by 21
ISPAD Clinical Practice Consensus Guidelines 2022: Ramadan and other religious fasting by young people with diabetes
Deeb, A., Babiker, A. M. I., Sedaghat, S., Awwa, A. E., Gupta, K., Pulungan, A. B., Umar, U. I., Akanov, Z., Kalra, S., Zangen, D., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13447 · Cited by 21
Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes
Wretlind, A., Curovic, V. R., Suvitaival, T., Theilade, S., Tofte, N., Winther, S. A., Vilsbøll, T., Vestergaard, H., Rossing, P. R., & Legido‐Quigley, C. (2023) · Diabetes · doi:10.2337/db23-0052 · Cited by 21
Self-citation
Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis
Bahardoust, M., Mousavi, S., Yariali, M., Haghmoradi, M., Hadaegh, F., Khalili, D., & Delpisheh, A. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01309-y · Cited by 21
Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment
Sampani, E., Sarafidis, P. A., & Papagianni, A. A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764532 · Cited by 24
Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture
Rossing, P. R., Persson, F., Frimodt‐Møller, M., & Hansen, T. W. (2020) · Diabetes · doi:10.2337/dbi19-0038 · Cited by 21
Self-citation
Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
Pratley, R. E., Crowley, M. J., Gislum, M., HERTZ, C. L., Jensen, T. B., Khunti, K., Mosenzon, O., & Buse, J. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00994-9 · Cited by 24
Self-citation
Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry
Arnold, S. V., GOSCH, K. L., Kosiborod, M., Wong, N. D., Sperling, L. S., Newman, J. D., Gamble, C. L., Hamersky, C. M., RAJPURA, J. R., & Vaduganathan, M. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.05.002 · Cited by 20
Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health
Yang, J., Gu, Y., Chen, H., Wang, H., Hong, L., Li, B., & Yang, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1453825 · Cited by 20
Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
Robinson, S. J., Boye, K. S., Mody, R., Strizek, A., Кониг, М., Malik, R., & Kennedy‐Martin, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00839-5 · Cited by 21
A Multidisciplinary Approach for Improving Quality of Life and Self-Management in Diabetic Kidney Disease: A Crossover Study
Helou, N., Talhouedec, D., Shaha, M., & Zanchi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072160 · Cited by 23
Factors associated with quality of life among elderly patients with type 2 diabetes mellitus: the role of family caregivers
Zan, H., Meng, Z., Li, J., Zhang, X., & Liu, T. (2024) · BMC Public Health · doi:10.1186/s12889-024-17917-z · Cited by 33
Role of Metformin in Various Pathologies: state-of-the-art Microcapsules for Improving Its Pharmacokinetics
Gedawy, A., Al‐Salami, H., & Dass, C. R. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0102 · Cited by 19
Poor Control of Plasma Triglycerides Is Associated with Early Decline of Estimated Glomerular Filtration Rates in New-Onset Type 2 Diabetes in China: Results from a 3-Year Follow-Up Study
Wang, C., Wang, L., Liang, K., Yan, F., Hou, X., Liu, F., Chen, L., & FOTI, D. P. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3613041 · Cited by 21
Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57)
Ishigaki, Y., Strizek, A., Aranishi, T., Arai, N., Imaoka, T., Cai, Z., & Maegawa, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00977-w · Cited by 20
Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class
Bain, E., & Bain, S. C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 21
Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM?
Zhou, Z., Mingyue, X., Xiong, P., Yuan, J., Zheng, D., & Piao, S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01479-6 · Cited by 19
Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes
Zannad, F. M., McGuire, D. K., & Ortíz, A. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20050 · Cited by 20
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 20
Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy
Lee, K. A., Park, T. S., & Jin, H. Y. (2020) · Endocrine · doi:10.1007/s12020-020-02473-4 · Cited by 19
Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population
Oyagüez, I., Peralta, F. G., Artola, S., Carrasco-Sánchez, F. J., Carretero‐Gómez, J., Soidán, F. J. G., Gómez‐Huelgas, R., Merino-Torres, J. F., & Pérez, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01064-4 · Cited by 24
Association of Atherogenic Index of Plasma With Angiographic Progression in Patients With Suspected Coronary Artery Disease
Shui, X., Chen, Z., Wen, Z., Tang, L., Tang, W., Liao, Y., Wu, Z., & Chen, L. (2022) · Angiology · doi:10.1177/00033197221080911 · Cited by 19
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M. J., Rodbard, H. W., Sattar, N. A., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 19
Self-citation
Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus
Nasykhova, Y. A., Barbitoff, Y. A., Tonyan, Z. N., Danilova, M. M., Nevzorov, I. A., Komandresova, T. M., Mikhailova, A. A., Vasilieva, T., Glavnova, O. B., Yarmolinskaya, M. I., et al. (2022) · Genes · doi:10.3390/genes13081310 · Cited by 19
Longitudinal deep learning clustering of Type 2 Diabetes Mellitus trajectories using routinely collected health records
Manzini, E., Vlacho, B., Franch‐Nadal, J., Escudero, J., Génova, A., Reixach, E., Andrés, E., Pizarro, I., Portero, J. L., Mauricio, D., et al. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104218 · Cited by 26
The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study
Zhang, Z., Dai, W., Weng, S., Luo, M., Fu, J., Zadroga, J. A., Spolitu, S., & Peng, D. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-1201-6 · Cited by 19
Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
Home, P. D., Blonde, L., Kalra, S., Ji, L., Guyot, P., Brulle-Wohlhueter, C., Murray, E. M., Shah, R., Sayre, T., & Shaunik, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14148 · Cited by 19
SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies
Qiu, M., Ding, L., Zhang, M., Lin, J.-H., Gu, J., Zhou, X. L., Tang, Y., Xu-bin, W., & Liu, S.-Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105175 · Cited by 18
Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
Ando, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Lunder, M., Janić, M., & Šabović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062796 · Cited by 20
Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
Norrbacka, K., Sicras-Mainar, A., Lebrec, J., Artime, E., Díaz, S., Tofé-Povedano, S., Hernández, I., & Romera, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01039-5 · Cited by 17
Metformin in patients with type 2 diabetes mellitus and heart failure: a review
Kułaczkowska, Z., Wróbel, M. P., Rokicka, D., Gąsior, M., & Strojek, K. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0033 · Cited by 19
The Nephroprotective Properties of Extracellular Vesicles in Experimental Models of Chronic Kidney Disease: a Systematic Review
Nowak, N., Yamanouchi, M., & Satake, E. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10189-9 · Cited by 18
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
Lingvay, I., Bauer, R., Baker‐Knight, J., Lawson, J., & Pratley, R. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab905 · Cited by 21
Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Doni, K., Bühn, S., Weise, A., Mann, N., Heß, S., Sönnichsen, A. C., Pieper, D., Thürmann, P., & Mathes, T. (2022) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986211072383 · Cited by 19
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Tanaka, A., & Node, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01191-5 · Cited by 19
Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Zhao, L.-M., Zhan, Z.-L., Ning, J., & Qiu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751496 · Cited by 18
Comparative efficacy of exercise modalities for general risk factors, renal function, and physical function in non-dialysis chronic kidney disease patients: a systematic review and network meta-analysis
Liu, C., Yang, J., Li, H., Deng, Y., He, P., Zhang, J., Chen, S., Chen, S., Wang, X., & Zhang, M. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2373272 · Cited by 19
Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
Martínez‐Vizcaíno, V., Díez‐Fernández, A., Álvarez‐Bueno, C., Alfonso, J. M., & Cavero‐Redondo, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122713 · Cited by 19
Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study
Goderis, G., Vaes, B., Mamouris, P., Craeyveld, E. V., & Mathieu, C. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1508-3912 · Cited by 18
Self-citation
Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021
Rossing, P., & Epstein, M. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.11.019 · Cited by 18
Self-citation
Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
Hao, Z., Sun, Y., Li, G., Shen, Y., Wen, Y., & Liu, Y. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00949-0 · Cited by 18
The impact of sodium–glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials
Teo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
Prediction models for risk of diabetic kidney disease in Chinese patients with type 2 diabetes mellitus
Sun, L., Wu, Y., Hua, R., & Zou, L. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2113797 · Cited by 18
Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes
Bell, D. S. H., McGill, J. B., & Jerkins, T. W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15181 · Cited by 18
Genome-Wide Association Study Identifies Pharmacogenomic Variants Associated With Metformin Glycemic Response in African American Patients With Type 2 Diabetes
Wu, B., Yee, S. W., Xiao, S., Xu, F., Sridhar, S. B., Yang, M., Hochstadt, S., Cabral, W., Lanfear, D. E., Hedderson, M. M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2494 · Cited by 18
Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
Maigret, L., Baslé, L., Châtelet, V., Écotière, L., Perrin, P., Golbin, L., Bertrand, D., Anglicheau, D., Poulain, C., Garrouste, C., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.11.033 · Cited by 20
New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective
Katsiki, N., Ferrannini, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154218 · Cited by 19
Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies
Koufakis, T., Grammatiki, M., & Kotsa, K. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.10.005 · Cited by 18
Efficacy and safety of adding sotagliflozin, a dual sodium‐glucose co‐transporter ( SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m 2
Danne, T., Edelman, S. V., Frías, J. P., Ampudia‐Blasco, F. J., Banks, P., Jiang, W., Davies, M. J., & Sawhney, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14271 · Cited by 18
Self-citation
Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations
Elnaem, M. H., Mansour, N. O., Nahas, A. R. F., Baraka, M. A., Elkalmi, R. M., & Cheema, E. U. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s285191 · Cited by 18
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.07.003 · Cited by 19
Medications adherence post‐primary percutaneous coronary intervention in acute myocardial infarction: A population‐based cohort study
Rahhal, A. A. A., Mahfouz, A., Khir, F., Okleh, N., Aljundi, A. H., Alkhalaila, O., Hamid, Y., Al‐Amri, M., Al‐Yafei, S. A., Suwaidi, J. M. S. A., et al. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13348 · Cited by 19
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?
Sharma, A., Aziz, H., Verma, S., Abramson, B. L., Choi, R., Chua, G. L., Connelly, K. A., Honos, G. N., Mancini, G. B. J., Ramer, S. A., et al. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000892 · Cited by 19
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Adeghate, E. A., Kalász, H., Jaberi, S. A., Adeghate, J. O., & Tekes, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1865914 · Cited by 19
Safety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
New Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 17
Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 17
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 19
Long-Term Glycemic Variability and Risk of Cardiovascular Events in Type 2 Diabetes: A Meta-Analysis
Wang, T., Zhang, X., & Liu, J. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1730-5029 · Cited by 19
Application of a Novel Biosensor for Salivary Conductivity in Detecting Chronic Kidney Disease
Lin, C., Tsai, Y., Lu, Y.-P., Yang, J., Chen, M., Huang, T., Weng, R.-C., & Tung, C. (2022) · Biosensors · doi:10.3390/bios12030178 · Cited by 17
In vivo and in vitro characterization of GL0034 , a novel long‐acting glucagon‐like peptide ‐1 receptor agonist
Jones, B. J., BURADE, V. S., Akalestou, E., Manchanda, Y., Ramchunder, Z., Carrat, G., Nguyen‐Tu, M., Marchetti, P., Piemonti, L., Leclerc, I., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14794 · Cited by 17
Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach
Dahabiyeh, L. A., Mujammami, M. H., AlMalki, R. H., Arafat, T., Benabdelkamel, H., Alfadda, A. A., & Rahman, A. M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911478 · Cited by 23
Effect of Inulin Intervention on Metabolic Control and Methylation of INS and IRS1 Genes in Patients with Type 2 Diabetes Mellitus
Martínez‐Ramírez, O. C., Salazar-Piña, D. A., Cerón-Ramírez, X., Rubio-Lightbourn, J., Torres-Romero, F., Casas-Ávila, L., & Hernández, C. C. (2022) · Nutrients · doi:10.3390/nu14235195 · Cited by 18
Safety, pharmacokinetics and pharmacodynamics of HRS ‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
Wu, J., Zhou, R., Zhang, Q., Zhang, Q., Qin, H., Ye, Z., Xu, Y., Feng, S., Shu, C., Shen, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15383 · Cited by 17
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Leehey, D. J. (2020) · Kidney360 · doi:10.34067/kid.0001252019 · Cited by 18
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
Tanaka, A., Shimabukuro, M., Okada, Y., Sugimoto, K., Kurozumi, A., Torimoto, K., Hirai, H., Node, K., & the PROCEED trial investigators (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01065-w · Cited by 17
What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline
Johansson, K. S., Sonne, D. P., Knop, F. K., & Christensen, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1791078 · Cited by 17
GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
Qiu, M., Ding, L., Zhang, M., Lin, J.-H., Xu-bin, W., & Huang, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00912-z · Cited by 17
Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management
Kanumilli, N., Brunton, S., Cos, X., Deed, G., Kushner, P. R., Lin, P., & Nolte, J. E. S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107813 · Cited by 17
Differences in initial versus recurrent diabetic foot ulcers at a specialized tertiary diabetic foot care center in China
Cheng, Y., Zu, P., Zhao, J., Shi, L., Shi, H., Zhang, M., & Wang, A. (2021) · Journal of International Medical Research · doi:10.1177/0300060520987398 · Cited by 17
Cardiovascular benefit of SGLT2 inhibitors
Mohebi, R., & Januzzi, J. L. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1993439 · Cited by 17
Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis
Qiu, M., Ding, L., Xu-bin, W., Liu, S.-Y., & Zhou, H. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000916 · Cited by 17
Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?
CHENG, A. Y. Y. (2021) · Circulation · doi:10.1161/circulationaha.120.053058 · Cited by 17
Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes
Ramanathan, R., Lee, J. Y., Dalton, J., Lin, R. T., Lee, I., Gonzalez, C., Shaw, J. D., Schroeder, G. D., Kepler, C. K., Spitnale, M. J., et al. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.01287 · Cited by 17
Telehealth Encourages Patients with Diabetes in Racial and Ethnic Minority Groups to Return for in-Person Ophthalmic Care During the COVID-19 Pandemic
Ramsey, D. J., Lasalle, C. C., Anjum, S., Marx, J. L., & Roh, S. (2022) · Clinical ophthalmology · doi:10.2147/opth.s368972 · Cited by 16
Thiourea derivatives inhibit key diabetes‐associated enzymes and advanced glycation end‐product formation as a treatment for diabetes mellitus
Ullah, I., Hassan, M., Khan, K. M., Sajid, M., Umar, M., Hassan, S., Ullah, A., El‐Serehy, H. A., Charifi, W., & Yasmin, H. (2022) · IUBMB Life · doi:10.1002/iub.2699 · Cited by 16
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
Neumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 17
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
Yang, Y., Min, K. W., Park, S., Kim, K., Yu, J. M., Hong, E., Cho, S., Won, K. C., Kim, Y. H., Oh, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15080 · Cited by 16
Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
Zhang, Y., Xie, P., Li, Y., Chen, Z., & Shi, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142003 · Cited by 16

Authors: Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
Affiliations: University of North Carolina at Chapel Hill (US)
Harvard University (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
University of Copenhagen (DK)
Università Cattolica del Sacro Cuore (IT)
Universitair Ziekenhuis Leuven (BE)
Duke University (US)
University of Leicester (GB)
Corresponding author: Davies, Melanie J.
ORCID: Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-19
Volume: 43
Issue: 2
Pages: 487-493
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dci19-0066
PMC: PMC6971782
OpenAlex: W4253996779
Cited by: 1,192
References: 21
Citations by year: 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
FWCI: 155.76
Type: journal article
Language: en
Update notices: correction (2020-07-01)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 32 d)
Locations: Diabetes Care (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
Lirias (submittedVersion)
PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders: American Diabetes Association
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks